Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials-Reference-Cited by-同舟云学术

Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials

Published:2020-03-24 Issue:2 Volume:25 Page:171-177
ISSN:1085-9489
Container-title:Journal of the Peripheral Nervous System
language:en
Short-container-title:J Peripher Nerv Syst

Author:

Bruna Jordi¹²^ORCID,Argyriou Andreas A.³⁴^ORCID,Anastopoulou Garifallia G.³,Alemany Montse¹,Nadal Ernest⁵,Kalofonou Foteini⁶,Piulats Josep M.⁷,Simó Marta¹,Velasco Roser¹²^ORCID,Kalofonos Haralabos P.³^ORCID

Affiliation:

1. Hospital Universitari de Bellvitge‐ICO l'Hospitalet, IDIBELL, l'Hospitalet de LlobregatUnit of Neuro‐Oncology Barcelona Spain

2. Institute of Neurosciences and Department of Cell Biology, Physiology and ImmunologyUniversitat Autònoma de Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Bellaterra Spain

3. Department of Medicine, Division Oncology, Medical SchoolUniversity Hospital of Patras Rion‐Patras Greece

4. Neurology DepartmentSaint Andrew's General Hospital of Patras Patras Greece

5. Thoracic Oncology UnitICO l'Hospitalet, IDIBELL, l'Hospitalet de Llobregat Barcelona Spain

6. Department of Oncology, Garry Weston CentreHammersmith Hospital, Imperial NHS Healthcare Trust London UK

7. Department of Medical OncologyICO l'Hospitalet, IDIBELL, l'Hospitalet de Llobregat Barcelona Spain

Publisher

Wiley

Subject

Clinical Neurology,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jns.12371

Reference30 articles.

1. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

2. Not All Immune Checkpoints Are Created Equal

3. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials

4. Immune checkpoint inhibitors‐induced neuromuscular toxicity: from pathogenesis to treatment;Psimaras D;J Peripher Nerv Syst,2019

5. Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study;The Lancet Regional Health - Europe;2024-09

2. Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action;Brain Sciences;2024-07-29

3. Recent insights into haematology and peripheral nerve disease;Current Opinion in Neurology;2024-06-10

4. Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach;Expert Opinion on Drug Safety;2024-06-03